Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Surgery
Interventions: Surgical wound closure techniques, Surgical wound closure techniques (Comparator); Procedure
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Kidney Transplantation
Interventions: basiliximab, rabbit anti-thymocyte globulin, tacrolimus, alemtuzumab, mycophenolate mofetil, steroids; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 22 more

Conditions: Migraine
Interventions: Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1,335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 37
States / cities: Hazel Green, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 30 more

Conditions: Obesity
Interventions: McGrath, GlideScope, Direct Macintosh Laryngoscopy, Video-Mac; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-inflammatory Joint Diseases
Interventions: Total hip replacement; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 8
States / cities: Little Rock, Arkansas • Orange, California • Palm Bay, Florida + 5 more

Conditions: Acute Low Back Pain
Interventions: Naproxen, Cyclobenzaprine, Oxycodone/ acetaminophen; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years to 64 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Multiple Myeloma
Interventions: Elranatamab, Standard of care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CMX-2043, Placebo control; Drug
Lead sponsor: Ischemix, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Worcester, Massachusetts • Durham, North Carolina

Conditions: Metabolic Acidosis
Interventions: Sodium bicarbonate, Tris-hydroxymethyl Aminomethane; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Delayed Healing
Interventions: PICO; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois • The Bronx, New York • Cleveland, Ohio

Conditions: Focus: Estrogen-free Oral Contraception
Interventions: Ulipristal Acetate; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Urinary Bladder Neoplasms
Interventions: Durvalumab, Olaparib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Goodyear, Arizona • Fort Myers, Florida + 9 more

Conditions: Parkinson Disease
Interventions: Telemedicine, Usual care; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 30 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ovarian Neoplasm
Interventions: KU-0059436 (AZD2281)(PARP inhibitor); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Larotrectinib(Vitrakvi, BAY2757556), Data on other treatments; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Type 2 Diabetes Mellitus
Interventions: Diabetes Medication Choice Cards; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 6
States / cities: Albert Lea, Minnesota • Kasson, Minnesota • Mankato, Minnesota + 3 more

Conditions: Central Precocious Puberty
Interventions: Triptorelin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 2 Years to 9 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 11
States / cities: Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 8 more

Conditions: Psoriasis
Interventions: Guselkumab, Placebo, Secukinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,048 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Oceanside, California + 38 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 79 Years · Male only
Enrollment: 3,265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more

Conditions: Endometrial Neoplasms
Interventions: PF-05212384; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 11 more

Conditions: Third Degree Burn, Burns, Wound Infection, Degloving Injury
Interventions: StrataGraft Skin Tissue, Cadaver allograft; Biological · Procedure
Lead sponsor: Stratatech, a Mallinckrodt Company; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Phoenix, Arizona • Madison, Wisconsin

Conditions: Bacterial Infections
Interventions: IV Vancomycin plus IV Aztreonam, Ceftaroline; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 15
States / cities: Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more

Conditions: Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
Interventions: cardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication; Procedure · Behavioral · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 5,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 109
States / cities: Birmingham, Alabama • Yuma, Arizona • Beverly Hills, California + 82 more

Conditions: Adult Primary Care Patients
Interventions: Integrative medicine primary care model; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Study of Sutures Versus Staples for Skin Closure After Surgical Procedures of Hip

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Comparative Effectiveness of Intubating Devices in the Morbidly Obese

Metal on Metal Versus Ceramic on Metal Hip Replacement

A Randomized Study of Three Medication Regimens for Acute Low Back Pain

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy

A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients

PICO Breast Reduction Clinical Study Looking at Incision Healing Complications

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing- A Comparative Effectiveness Study

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

IMPACT - Integrative Medicine PrimAry Care Trial